Price$0.90+0.03 (+2.87%)
2026-03-062026-06-09
News · 26 weeks28-90%
2025-12-142026-06-07
Mix1790d
- SEC Filings9(53%)
- Earnings3(18%)
- Other3(18%)
- Insider1(6%)
- Leadership1(6%)
Latest news
25 items- PRAfter Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast InsteadConexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)
- SECSEC Form 10-Q filed by TELA Bio Inc.10-Q - TELA Bio, Inc. (0001561921) (Filer)
- SECTELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio Reports First Quarter 2026 Financial ResultsMALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Announced strategic board refreshment plan to be effective at the conclusion of the 2026 Annual Meeting on June 9, 2026;Noted the U.S. commercial organization is fully staffed at planned 2026 levels;Delivered revenue of $19.1 million in the first quarter of 2026, representing growth of 3% over the prior year period;Accelerated European revenue growth to 41% over the prior year period, with continued moment
- PRTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 89,250 shares of its common stock to 12 newly-hired employees, with a grant date of May 5, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her accep
- SECSEC Form DEFA14A filed by TELA Bio Inc.DEFA14A - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form DEF 14A filed by TELA Bio Inc.DEF 14A - TELA Bio, Inc. (0001561921) (Filer)
- SECTELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update8-K - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,
- PRTELA Bio to Announce First Quarter 2026 Financial ResultsMALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2026 financial results on Tuesday, May 12, 2026. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the
- SECSEC Form S-8 filed by TELA Bio Inc.S-8 - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form 10-K filed by TELA Bio Inc.10-K - TELA Bio, Inc. (0001561921) (Filer)
- SECTELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio Reports Fourth Quarter and Full Year 2025 Financial ResultsMALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered revenue of $20.9 million in the fourth quarter and $80.3 million for the full year 2025, an 18% and 16% increase, respectively, from the corresponding periods of 2024;Expanded the sales force to 88 quota-carrying representatives as of today under the leadership of commercial management added at midyear;Announcing promotion of Howard Langstein, MD, FACS to Chief Medical Officer
- SECTELA Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - TELA Bio, Inc. (0001561921) (Filer)
- INSIDERNew insider Langstein Howard N. claimed ownership of 71,347 shares (SEC Form 3)3 - TELA Bio, Inc. (0001561921) (Issuer)
- PRTELA Bio to Announce Fourth Quarter and Full Year 2025 Financial ResultsMALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15
- INSIDERChief Executive Officer Koblish Antony was granted 176,000 shares and covered exercise/tax liability with 28,025 shares, decreasing direct ownership by 0.66% to 586,210 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERChief Business Officer Firestone Gregory A. was granted 37,000 shares and covered exercise/tax liability with 5,541 shares, increasing direct ownership by 29% to 139,307 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERChief Technology Officer Talmo Paul was granted 57,000 shares and covered exercise/tax liability with 7,446 shares, increasing direct ownership by 40% to 173,436 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERPresident Blizard Jeffrey was granted 86,000 shares, increasing direct ownership by 72% to 205,125 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERCOO and CFO Cuca Roberto was granted 57,000 shares and covered exercise/tax liability with 10,014 shares, increasing direct ownership by 22% to 257,377 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERChief Accounting Officer Smeykal Megan was granted 32,850 shares and covered exercise/tax liability with 2,808 shares, increasing direct ownership by 82% to 66,873 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- PRTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 8,550 shares of its common stock to three newly-hired employees, with a grant date of February 18, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or
TELA FAQ
7 questionsWhat does TELA Bio Inc. do?
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be...Where does TELA stock trade?
TELA Bio Inc. (TELA) is listed on NASDAQ.What sector and industry is TELA in?
TELA Bio Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did TELA Bio Inc. go public?
TELA Bio Inc. (TELA) completed its IPO in 2019.What are analysts saying about TELA?
TELA Bio Inc. has had 2 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral with a $200.00 price target on 2025-03-21.What companies are similar to TELA?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare TELA side-by-side with any of them on Quantisnow.How can I track TELA on Quantisnow?
Quantisnow aggregates TELA Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TELA to receive live email and push alerts on every new disclosure.